Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders
Alline Cristina Campos, Manoela V. Fogaça, Franciele Franco Scarante, Sâmia R L Joca, Amanda J. Sales, Felipe V. Gomes, Andreza Buzolin Sonego, Naielly S. Rodrigues, Ismael Galve-Roperh, Francisco Silveira Guimarães
Frontiers in Pharmacology May 23, 2017 DOI: 10.3389/fphar.2017.00269 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Cannabidiol (CBD) |
| Topics | CBD |
| Citations | 176 |
| Key findings | The authors propose that CBD's beneficial effects in psychiatric disorders are linked to neuroplastic changes, including protection against stress-induced reductions in hippocampal neurogenesis and dendrite spine density, prevention of microglia activation and parvalbumin-positive GABA neuron loss in a schizophrenia model, and modulation of cell-fate pathways such as autophagy in neurodegenerative models. |
Abstract
Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia. More recently, it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration. These changes and their possible association with CBD beneficial effects in psychiatric disorders are reviewed here.
Comparable studies
Other narrative reviews on CBD, most cited first.
Citations in the library
Cited by 6
- Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age Frontiers in Immunology September 21, 2018
- Novel rapid treatment options for adolescent depression. Pharmacological Research March 1, 2024
- Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. Neuropsychopharmacology December 1, 2024
- Cannabidiol exhibits anxiolytic-like effects and antipsychotic-like effects in mice models. Neuroscience Letters March 1, 2024
- Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial Cannabis and Cannabinoid Research July 26, 2023
and 1 more in the library
Cites 10
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase Science December 6, 2007
- Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing Archives of General Psychiatry 2009
- Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol The International Journal of Neuropsychopharmacology September 24, 2009
- Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain Frontiers in Pharmacology 2014
and 5 more in the library